Blood Transfusion Diagnostics Market - By Product (Instruments, Reagents & Kits), By Application (Blood Grouping, Disease Screening), By End-use (Hospitals, Diagnostic Laboratories, Blood Banks) & Forecast, 2023 – 2032

Blood Transfusion Diagnostics Market - By Product (Instruments, Reagents & Kits), By Application (Blood Grouping, Disease Screening), By End-use (Hospitals, Diagnostic Laboratories, Blood Banks) & Forecast, 2023 – 2032

Blood Transfusion Diagnostics Market Size

Blood Transfusion Diagnostics Market size was valued at around USD 4.6 billion in 2022 and is estimated to reach USD 8.8 billion by the end of 2032. Increasing prevalence of chronic diseases and blood related disorders is expected to augment the global market growth.
 

Increasing demand for blood and blood components due to rising trauma and accident cases has surged the market growth opportunities across the globe. Technological advancements pertaining to blood transfusion diagnostics including precise and accurate instruments have increased the product demand. The development of technologically improved solutions at competitive prices by major participants in the market would assist blood transfusion diagnostics become more widely used. Product launch is one of the main methods used by market participants to maintain competitiveness and have a diverse product portfolio. The aforementioned factors are therefore expected to accelerate market expansion.

Blood transfusion diagnostics refers to a series of laboratory tests and procedures performed to determine the compatibility of donor and recipient blood before a blood transfusion. Blood transfusion diagnostics is intended to ensure that the transfused blood is safe and compatible with the receiver’s blood, in order to prevent potentially life-threatening transfusion reactions and other complications.
 

The high cost of blood transfusion diagnostics equipment may impede market expansion over the anticipated time period. The incorporation of new technologies into advanced blood screening devices raises the price of blood transfusion diagnostics equipment and restricts the industry's expansion. Financial limitations may impede the growth of businesses, particularly in economically developing nations and lower income groups. Additionally, high cost of blood transfusion diagnostics instruments will adversely affect the market growth in the coming years. An average cost of blood screening instruments is approximately USD 16,000 to USD 45,000; while advanced transfusion diagnostics instruments can range over USD 50,000 and may vary according to the technology used as well as the number of tests an instrument can perform.
 

Growing concern pertaining to the rising costs of these instruments is further compounded by the increasing demand for blood and blood components requiring these devices for diagnosis. The market growth can be hindered in developing economies having comparatively low-income levels attributed to the high costs. Thus, the high-end pricing associated with advanced blood transfusion diagnostics instruments may drive down the acceptance rate of these devices, further hampering the business expansion.
 

COVID-19 Impact

The onset of the COVID-19 pandemic was an unprecedented event impacting the public health and led to an incremental surge in the number of hospitalizations. The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during 2020 & initial phase of 2021. This has resulted in delay or postponing several medical and diagnostics procedures. The COVID-19 pandemic had a negative impact on the blood transfusion diagnostics market, as it impacted certain aspects of transfusion such as donor eligibility, donor availability, and availability of healthcare professionals to collect, store, and channelize blood into its components. During the initial phase of COVID-19 pandemic, improvised standard operating protocols were enacted at donor sites that affected the blood collection volume. Also, community donor events were either cancelled or postponed due to fear of infection, logistical constrains, and the time required to implement revised safety protocols.
 

However, the decreasing infection rate and number of patients of COVID-19, as well as increasing volume of blood donations and blood screening propelled the market growth from second quarter of 2021. Thus, the reduced number of COVID-19 cases and implementation of subsequent strategies by government and non-government organizations is anticipated to drive the blood transfusion diagnostics industry growth in the upcoming years.
 

Blood Transfusion Diagnostics Market Trends

Increasing prevalence of chronic diseases and blood related disorders is proving beneficial for the market growth. Significant upsurge in blood related disorders has augmented the demand for blood transfusion among patients in several healthcare facilities. Some of the major disorders including thrombocytopenia, hemophilia, and leukocytosis among others require blood transfusion for the diagnosis and treatment.
 

Additionally, availability of advanced blood screening devices offers safe and effective blood transfusion for the recipients. The incidence of blood diseases is further forecasted to increase substantially in the elderly population aged 65 years or above. The rise in blood diseases and related mortality offers immense potential for business growth and opportunity for the market players to establish and penetrate the untapped market. Thus, the growing prevalence of chronic and blood-related disorders is expected to expedite the blood transfusion diagnostics industry statistics.
 

Blood Transfusion Diagnostics Market Analysis 

Based on product, the Blood Transfusion Diagnostics market is segmented as reagents & kits and instruments. The reagents & kits held a majority market value of USD 3 billion in 2022. This high market share is owing to several benefits offered by reagents & kits in precise and accurate screening and management of blood transfusion diagnostics. The expanding elderly population base along with increasing prevalence of chronic diseases requiring prolonged hospital stays will boost the segmental growth in near future. The growing patient awareness regarding reagents & kits, home diagnostics and self-testing is anticipated to boost market adoption of blood transfusion diagnostics, thereby propelling segmental growth. In order to perform more blood transfusions, reagents and kits are used more frequently and are expended at high rate in blood screening procedures, thereby fuelling the business landscape.
 

Based on application, the market is segmented as Blood grouping and disease screening. Disease screening is further bifurcated as serological disease screening and molecular disease screening. The disease screening held a dominant market share of around 40% in 2022 and is expected to grow at a lucrative pace by 2032. Increasing incidence of transmitted infection cases during blood transfusion has augmented the product demand in several healthcare facilities.
 

Additionally, increasing safety concerns related to screening of blood donors to maintain safe transfusion and availability of technologically advanced blood screening products is expected to drive the market growth. Furthermore, growing focus of various research institutes on performing experiments with serological testing approaches is expected to bring breakthrough technologies for blood transfusion diagnostics market expansion.
 

Based on end-use the blood transfusion diagnostics market is segmented as hospitals, diagnostic laboratories, blood banks and others. The diagnostic laboratories segment is anticipated to grow at 6.6% CAGR through 2032. This market share is owing to the rising preference for precise blood screening coupled with growing number of diagnostic laboratories, etc. Further, diagnostic laboratories offer same-day test results along with cost-effective, high-quality services and can reduce medical expenses. Moreover, the availability of a comprehensive range of reagent & kits and instruments incorporating advanced technology for screening variety of blood components and disorders is expected to drive the demand for these healthcare settings. Thus, the high-quality services and growing number of blood transfusion diagnostics at diagnostic laboratories are anticipated to expedite the business demand.
 

U.S. dominated the North American region with majority market share and a revenue of USD 1.8 billion in 2022 and is anticipated to expand at a significant pace from 2023-2032. This majority market share is attributable to several factors such as the rising prevalence of chronic diseases and blood disorders rising healthcare expenditure along with surged product adoption across the country. The presence of prominent players are engaged in the novel technologies adoption that facilitates the industrial expansion in the region. The high prevalence of chronic & blood diseases and the rising hospital admission in the region emphasize the growing need for blood transfusion in related procedures. Furthermore, the availability of advanced technologies that enhance the quality of blood screening and blood transfusion are some other factors that facilitate the blood transfusion diagnostics market in the region.
 

Blood Transfusion Diagnostics Market Share

Some of the major market players operating in the blood transfusion diagnostics industry are

• Abbott Laboratories
• BAG Healthcare GmBH
• Bio-Rad Laboratories, Inc
• Danaher Corporation
• Diagnostica Stago
• DiaSorin S.p.A., F.
• Hoffmann-La Roche Ltd
• Grifols S.A.
• Hologic, Inc.
• Immucor Inc
• Merck KGaA
• Ortho Clinical Diagnostics
• Quotient Ltd
•  Thermo Fisher Scientific Inc.

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
 

Blood Transfusion Diagnostics Industry News

• In May 2021, Ortho Clinical Diagnostics announced the launch of ORTHO VISION Swift and ORTHO VISION Max Swift Analysers. These analysers provide enhanced blood transfusion diagnostics and offers labs with more processing power, enhanced responsiveness, and advanced data security to ensure fast, accurate, and reliable test results. This innovative product launch helped the company to increase their product portfolio and enhance their business revenue.
   
• In March 2021, Bio-Rad Laboratories, Inc. announced a strategic partnership with Roche for providing InteliQ products Unity QC data management solutions to customers worldwide. These products and solutions offer a wide range of blood screening capabilities including immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, etc. This strategic partnership helped the company to increase their customer base and gain a competitive edge over its peers.
   

Blood transfusion diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million & Units from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Product, 2018 - 2032 (USD Million & Units)

• Instruments
• Reagents & Kits

By Application, 2018 - 2032 (USD Million)

• Blood Grouping
• Disease Screening
• Serological Disease Screening
• Molecular Disease Screening

By End-use, 2018 - 2032 (USD Million)

• Hospitals
• Diagnostic Laboratories
• Blood Banks
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Austria
  • Poland
  • Belgium
  • The Netherland
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Malaysia 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Peru 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Egypt